Q-omics provides the consensus-scored TNRC6A profile across patient tissues and cancer cell-line models. TNRC6A expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TNRC6A is differentially expressed in 7, with the highest sampling consensus in HNSC. Additionally, TNRC6A RNA expression shows 21,452 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, and UVM as cancer lineages where TNRC6A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TNRC6A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TNRC6A survival associations across molecular data types. TNRC6A RNA expression shows survival associations in the most cancer types (25), followed by mutation status (9) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TNRC6A RNA expression–survival associations across cancer types. High TNRC6A expression shows unfavorable associations in LGG, LUSC and UVM, but favorable associations in HNSC, ESCA and BRCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TNRC6A RNA expression.
This table summarizes TNRC6A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for TNRC6A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TNRC6A shows lower tumor expression in THCA and UCEC and higher tumor expression in HNSC, KIRP, KIRC and CHOL. The HNSC box plot shows higher TNRC6A RNA expression in tumor versus normal tissue (log2 FC = +0.911, t-test p < 0.001).
This table shows molecular features associated with TNRC6A in patient tissues and cancer cell lines. In patient samples, TNRC6A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TNRC6A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
